Psychopharmacological treatment and psychological interventions in irritable bowel syndrome

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Sinagra, Emanuele ^a   Romano, Claudia ^a   Cottone, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ASIMADOLINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXLOXIGLUMIDE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; FEDOTOZINE; GABAPENTIN; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OCTREOTIDE; PEXACERFONT; PREGABALIN; QUETIAPINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SOLABEGRON; SPASMOLYTIC AGENT; TOFISOPAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BLURRED VISION; CONSTIPATION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; IRRITABLE COLON; MENTAL DISEASE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEUROTRANSMISSION; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PANIC; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NERVE CELL; SINGLE DRUG DOSE; SOMNOLENCE; STRESS; XEROSTOMIA;

EID: 84866253309     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/486067     Document Type: Review

References (109)

1. Boyce P. M., Koloski N. A., Talley N. J., Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? American Journal of Gastroenterology 2000 95 11 3176 3183 2-s2.0-0033755606 10.1016/S0002-9270(00) 01990-0
2. Hillilä M. T., Färkkilä M. A., Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Alimentary Pharmacology and Therapeutics 2004 20 3 339 345 2-s2.0-4043134459 10.1111/j.1365-2036.2004.02034.x (Pubitemid 39062137)
3. Hungin A. P. S., Whorwell P. J., Tack J., Mearin F., The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Alimentary Pharmacology and Therapeutics 2003 17 5 643 650 2-s2.0-0037357895 10.1046/j.1365-2036.2003.01456.x (Pubitemid 36418887)
4. Mearin F., Badía X., Balboa A., Baró E., Caldwell E., Cucala M., Díaz-Rubio M., Fueyo A., Ponce J., Roset M., Talley N. J., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scandinavian Journal of Gastroenterology 2001 36 11 1155 1161 2-s2.0-17944363484 10.1080/00365520152584770 (Pubitemid 32917583)
5. Harvey R. F., Salih S. Y., Read A. E., Organic and functional disorders in 2000 gastroenterology outpatients. The Lancet 1983 1 8325 632 634 2-s2.0-0020663287 (Pubitemid 13152348)
6. Sainsbury A., Ford A. C., Review: treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therapeutic Advances in Gastroenterology 2011 4 2 115 127 2-s2.0-79953315976 10.1177/1756283X10387203
7. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C., Functional bowel disorders. Gastroenterology 2006 130 5 1480 1491 2-s2.0-33646201684 10.1053/j.gastro.2005.11.061
8. Surdea-Blaga T., Baban A., Dumitrascu D. L., Psychosocial determinants of irritable bowel syndrome. World Journal of Gastroenterology 2012 18 7 616 626 10.3748/wjg.v18.i7.616
9. Longstreth G. F., Thompson W. G., Chey W. D., Houghton L. A., Mearin F., Spiller R. C., Drossman D. A., Corazziari E., Delvaux M., Spiller R. C., Talley N. J., Thompson W. G., Whitehead W. E., Functional bowel disorders. Rome III: The Functional Gastrointestinal Disorders 2006 3rd McLean, Va, USA Degnon Associates 487 555
10. Drossman D. A., Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosomatic Medicine 1998 60 3 258 267 2-s2.0-0031812434 (Pubitemid 28279969)
11. Drossman D. A., Drossman D. A., Corazziari E., Delvaux M., Spiller R., Talley N. J., Thompson W. G., Whitehead W. E., The functional gastrointestinal disorders and the Rome III process. Rome III: The Functional Gastrointestinal Disorders 2006 3rd McLean, Va, USA Degnon Associates 1 30
12. Drossman D. A., The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 130 5 1377 1390 2-s2.0-33646201266 10.1053/j.gastro.2006.03.008
13. Richard Locke G., Zinsmeister A. R., Talley N. J., Fett S. L., Joseph Melton L., Familial association in adults with functional gastrointestinal disorders. Mayo Clinic Proceedings 2000 75 9 907 912 2-s2.0-0033827386
14. Aguas M., Garrigues V., Bastida G., Nos P., Ortiz V., Ponce J., Prevalence of irritable bowel syndrome in first-degree relatives of patients with inflammatory bowel disease. Quality of life and economic impact. Gastroenterology 2010 138 supplement 1 5 S627
15. Senn T. E., Carey M. P., Vanable P. A., Childhood and adolescent sexual abuse and subsequent sexual risk behavior: evidence from controlled studies, methodological critique, and suggestions for research. Clinical Psychology Review 2008 28 5 711 735 2-s2.0-42249094193 10.1016/j.cpr.2007.10.002 (Pubitemid 351551464)
16. Talley N. J., Fett S. L., Zinsmeister A. R., Melton L. J., Gastrointestinal tract symptoms and self-reported abuse: a population- based study. Gastroenterology 1994 107 4 1040 1049 2-s2.0-0028128956
17. Han C., Masand P. S., Krulewicz S., Peindl K., Mannelli P., Varia I. M., Pae C. U., Patkar A. A., Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. Journal of Clinical Pharmacy and Therapeutics 2009 34 1 79 88 2-s2.0-58149308277 10.1111/j.1365-2710.2008.00975.x
18. Drossman D. A., Leserman J., Nachman G., Li Z., Gluck H., Toomey T. C., Mitchell C. M., Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Annals of Internal Medicine 1990 113 11 828 833 2-s2.0-0025652130
19. Dumitrascu D. L., Stanculete M., Costin S., Dumitrascu D., Geographical differences in the report of sexual abuse in females with irritable bowel syndrome. Proceedings of the 19th World Congress on Psychosomatic Medicine August 2007 Québec, Canada
20. Beesley H., Rhodes J., Salmon P., Anger and childhood sexual abuse are independently associated with irritable bowel syndrome. British Journal of Health Psychology 2010 15 2 389 399 2-s2.0-77951589154 10.1348/135910709X466496
21. Koloski N. A., Talley N. J., Boyce P. M., A history of abuse in community subjects with irritable bowel syndrome and functional dyspepsia: the role of other psychosocial variables. Digestion 2005 72 2-3 86 96 2-s2.0-27144462034 10.1159/000087722 (Pubitemid 41507267)
22. Costa P. T., McCrae R. R., NEO PI-R Professional Manual (Revised NEO Personality Inventory and NEO Five-Factor Inventory) 1992 Odessa, Ukraine Psychological Assessment Resources
23. Chamorro-Premuzic T., Personality and Individual Differences 2007 Malden, Mass, USA Blackwell Publishing
24. Sifneos P. E., Alexithymia: past and present. American Journal of Psychiatry 1996 153 7 137 142 2-s2.0-0030018759 (Pubitemid 26235226)
25. Taylor G. J., Taylor H. S., McCallum M., Piper W. E., Alexithymia. Psychological Mindedness: A Contemporary Understanding 1997 Munich, Germany Lawrence Erlbaum Associates Personality & Clinical Psychology
26. Lazarus R. S., Folkman S., Stress, Appraisal and Coping 1984 New York, NY, USA Springer
27. Drossman D. A., Chang L., Schneck S., Blackman C., Norton W. F., Norton N. J., A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Digestive Diseases and Sciences 2009 54 7 1532 1541 2-s2.0-67349163863 10.1007/s10620-009-0792-6
28. Widiger T. A., Thomas A., Diagnosis and Statistical Manual of Mental Disorders 1994 4th Washington, DC, USA American Psychatric Publishing
29. Creed F. H., Levy R., Bradley L., Drossman D. A., Francisconi C., Naliboff B. D., Olden K. W., Drossman D. A., Corazzieri E., Delvaux M., Spiller R. C., Talley N. J., Thompson W. G., Whitehead W. E., Psychosocial aspects of functional gastrointestinal disorders. Rome III: The Functional Gastrointestinal Disorders 2006 3rd McLean, Va, USA Degnon Associates 295 368
30. Creed F., Ratcliffe J., Fernandes L., Palmer S., Rigby C., Tomenson B., Guthrie E., Read N., Thompson D. G., Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. British Journal of Psychiatry 2005 186 507 515 2-s2.0-20644451625 10.1192/bjp.186.6.507 (Pubitemid 40834871)
31. Whitehead W. E., Palsson O. S., Levy R. L., Von Korff M., Feld A. D., Turner M. J., Comorbid psychiatric disorders in irritable bowel (IBS) and inflammatory bowel disease (IBD). Gastroenterology 2003 124, article A398
32. Henningsen P., Zimmermann T., Sattel H., Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosomatic Medicine 2003 65 4 528 533 2-s2.0-0041843834 10.1097/01.PSY.0000075977.90337.E7 (Pubitemid 36900246)
33. Miller A. R., North C. S., Clouse R. E., Wetzel R. D., Spitznagel E. L., Alpers D. H., The association of irritable bowel syndrome and somatization disorder. Annals of Clinical Psychiatry 2001 13 1 25 30 2-s2.0-0034932036 10.1023/A:1009060731057 (Pubitemid 32660580)
34. North C. S., Downs D., Clouse R. E., Alrakawi A., Dokucu M. E., Cox J., Spitznagel E. L., Alpers D. H., The presentation of irritable bowel syndrome in the context of somatization disorder. Clinical Gastroenterology and Hepatology 2004 2 9 787 795 2-s2.0-4444253217 10.1016/S1542-3565(04)00350-7 (Pubitemid 39200717)
35. Locke G. R., Weaver A. L., Melton L. J., Talley N. J., Psychosocial factors are linked to functional gastrointestinal Disorders: a population based nested case-control study. American Journal of Gastroenterology 2004 99 2 350 357 2-s2.0-1442350422 10.1111/j.1572-0241.2004.04043.x (Pubitemid 38279880)
36. Talley N. J., Dennis E. H., Schettler-Duncan V. A., Lacy B. E., Olden K. W., Crowell M. D., Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. American Journal of Gastroenterology 2003 98 11 2454 2459 2-s2.0-0344496200 10.1111/j.1572-0241.2003.07699.x (Pubitemid 37448756)
37. Halder S. L. S., Locke G. R., Talley N. J., Fett S. L., Zinsmeister A. R., Melton L. J., Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Alimentary Pharmacology and Therapeutics 2004 19 2 233 242 2-s2.0-0842265199 10.1111/j.0269-2813.2004.01807.x (Pubitemid 38174892)
38. Holtmann G., Kutscher S. U., Haag S., Langkafel M., Heuft G., Neufang-Hueber J., Goebell H., Senf W., Talley N. J., Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia: a randomized, double-blind placebo-controlled crossover study. Digestive Diseases and Sciences 2004 49 4 672 679 2-s2.0-2942735405 10.1023/B:DDAS.0000026317.00071.75 (Pubitemid 38992561)
39. Jones M. P., Dilley J. B., Drossman D., Crowell M. D., Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterology and Motility 2006 18 2 91 103 2-s2.0-33645092151 10.1111/j.1365-2982.2005.00730.x
40. Eisendrath S. J., Kodama K. T., Fluoxetine management of chronic abdominal pain. Psychosomatics 1992 33 2 227 229 2-s2.0-0026586934
41. Hameroff S. R., Weiss J. L., Lerman J. C., Doxepin's effects on chronic pain and depression: a controlled study. Journal of Clinical Psychiatry 1984 45 3 47 52 2-s2.0-0021280966 (Pubitemid 14133698)
42. Pilowsky I., Barrow C. G., A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990 40 1 3 19 2-s2.0-0025095418 10.1016/0304-3959(90)91045-K (Pubitemid 20038531)
43. Gorard D. A., Libby G. W., Farthing M. J. G., Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Digestive Diseases and Sciences 1995 40 1 86 95 2-s2.0-0028842127 10.1007/BF02063948
44. Gilman A. G., Hardman J. G., Limbird L. E., Goodman & Gilman'S the Pharmacological Basis of Therapeutics 2001 10th New York, NY, USA McGraw-Hill
45. Camilleri M., Bueno L., de Ponti F., Fioramonti J., Lydiard R. B., Tack J., Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006 130 5 1421 1434 2-s2.0-33646179154 10.1053/j.gastro.2005.08.062
46. Drossman D. A., Thompson W. G., The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Annals of Internal Medicine 1992 116 12 1009 1016 2-s2.0-0026636839
47. Ford A. C., Talley N. J., Schoenfeld P. S., Quigley E. M. M., Moayyedi P., Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009 58 3 367 378 2-s2.0-61649089108 10.1136/gut.2008.163162
48. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt L. J., Chey W. D., An evidence-based position statement on the management of irritable bowel syndrome. The American Journal of Gastroenterology 2009 104 supplement 1 S1 S35
49. Abdul-Baki H., El Hajj I. I., Elzahabi L., Azar C., Aoun E., Skoury A., Chaar H., Sharara A. I., A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World Journal of Gastroenterology 2009 15 29 3636 3642 2-s2.0-70349572337 10.3748/wjg.15.3636
50. Masand P. S., Pae C. U., Krulewicz S., Peindl K., Mannelli P., Varia I. M., Patkar A. A., A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009 50 1 78 86 2-s2.0-61849161180 10.1176/appi.psy.50.1.78
51. Ladabaum U., Sharabidze A., Levin T. R., Zhao W. K., Chung E., Bacchetti P., Jin C., Grimes B., Pepin C. J., Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2010 8 1 42 48 2-s2.0-72049107445 10.1016/j.cgh.2009.09.008
52. Ford A. C., Moayyedi P., "Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2010 8 3 313 314 2-s2.0-77349109541 10.1016/j.cgh.2009.10.027
53. Yamaguchi K., Suzuki K., Niho T., Tofisopam, a new 2,3-benzodiazepine. Inhibition of changes induced by stress loading and hypothalamic stimulation. Canadian Journal of Physiology and Pharmacology 1983 61 6 619 625 2-s2.0-0020589291 (Pubitemid 13028469)
54. Lydiard R. B., Psychopharmacology in the treatment of irritable bowel syndrome. Primary Psychiatry 2007 14 4 40 50 2-s2.0-34248136461 (Pubitemid 46726202)
55. Saps M., Youssef N., Miranda A., Nurko S., Hyman P., Cocjin J., Di Lorenzo C., Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009 137 4 1261 1269 2-s2.0-70349420923 10.1053/j.gastro.2009.06.060
56. Bahar R. J., Collins B. S., Steinmetz B., Ament M. E., Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. Journal of Pediatrics 2008 152 5 685 689 2-s2.0-41849136545 10.1016/j.jpeds.2007.10.012
57. Kaminski A., Kamper A., Thaler K., Chapman A., Gartlehner G., Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database of Systematic Reviews 2011 7 CD008013 2-s2.0-79960994445
58. Camilleri M., Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clinical Pharmacology and Therapeutics 2012 91 1 44 59 10.1038/clpt.2011.261
59. Grover M., Dorn S. D., Weinland S. R., Dalton C. B., Gaynes B. N., Drossman D. A., Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Digestive Diseases and Sciences 2009 54 6 1284 1291 2-s2.0-67349132474 10.1007/s10620-009-0723-6
60. Iovino P., Azpiroz F., Domingo E., Malagelada J. R., The sympathetic nervous system modulates perception and reflex responses to gut distention in humans. Gastroenterology 1995 108 3 680 686 2-s2.0-0028946132 10.1016/0016-5085(95)90439-5
61. Horvath E. J., Horvath K., Hamori T., Fekete M. I., Anxyolitic 2, 3-benzodiazepines, their specific binding to the basal ganglia. Progress in Neurobiology 2000 60 309 342 10.1016/S0301-0082(99)00020-9
62. Leventer S. M., Kucharik R. F., Keogh J. C., Karen M., The potential of dextofisopam for treatment of irritable bowel syndrome and inflammatory bowel disease. The American Journal of Gastroenterology 2004 99 S279
63. Leventer S. M., Raudibaugh K., Frissora C. L., Kassem N., Keogh J. C., Phillips J., Mangel A. W., Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2008 27 2 197 206 2-s2.0-37149041916 10.1111/j.1365-2036.2007.03566.x (Pubitemid 350256611)
64. Olden K. W., The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectrums 2005 10 11 891 896 2-s2.0-28944431865 (Pubitemid 41784934)
65. Castedal M., Björnsson E., Abrahamsson H., Effects of midazolam on small bowel motility in humans. Alimentary Pharmacology and Therapeutics 2000 14 5 571 577 2-s2.0-0034051867 10.1046/j.1365-2036.2000.00741.x (Pubitemid 30240749)
66. Larauche M., Mulak A., Taché Y., Stress and visceral pain: from animal models to clinical therapies. Experimental Neurology 2012 233 1 49 67 10.1016/j.expneurol.2011.04.020
67. Houghton L. A., Fell C., Whorwell P. J., Jones I., Sudworth D. P., Gale J. D., Effect of a second-generation α 2 δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007 56 9 1218 1225 2-s2.0-34548127061 10.1136/gut.2006.110858 (Pubitemid 47300421)
68. Lee K. J., Kim J. H., Cho S. W., Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2005 22 10 981 988 2-s2.0-27744603267 10.1111/j.1365-2036.2005. 02685.x (Pubitemid 41634880)
69. Delvaux M., Louvel D., Lagier E., Scherrer B., Abitbol J. L., Frexinos J., The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999 116 1 38 45 2-s2.0-0032924832 10.1016/S0016-5085(99)70226-X (Pubitemid 29013491)
70. Delvaux M., Beck A., Jacob J., Bouzamondo H., Weber F. T., Frexinos J., Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2004 20 2 237 246 2-s2.0-3242878696 10.1111/j.1365-2036.2004. 01922.x (Pubitemid 38998223)
71. Mangel A. W., Bornstein J. D., Hamm L. R., Buda J., Wang J., Irish W., Urso D., Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2008 28 2 239 249 2-s2.0-45549083888 10.1111/j.1365-2036.2008.03730.x (Pubitemid 351861967)
72. Szarka L. A., Camilleri M., Burton D., Fox J. C., McKinzie S., Stanislav T., Simonson J., Sullivan N., Zinsmeister A. R., Efficacy of on-demand asimadoline, a peripheral κ -opioid agonist, in females with irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2007 5 11 1268 1275 2-s2.0-35548931920 10.1016/j.cgh.2007.07.011 (Pubitemid 350019057)
73. Cellek S., Thangiah R., Bassil A. K., Campbell C. A., Gray K. M., Stretton J. L., Lalude O., Vivekanandan S., Wheeldon A., Winchester W. J., Sanger G. J., Schemann M., Lee K., Demonstration of functional neuronal β 3-adrenoceptors within the enteric nervous system. Gastroenterology 2007 133 1 175 183 2-s2.0-34447109450 10.1053/j.gastro.2007.05.009 (Pubitemid 47031143)
74. Grudell A. B. M., Camilleri M., Jensen K. L., Foxx-Orenstein A. E., Burton D. D., Ryks M. D., Baxter K. L., Cox D. S., Dukes G. E., Kelleher D. L., Zinsmeister A. R., Dose-response effect of a β 3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. American Journal of Physiology 2008 294 5 G1114 G1119 2-s2.0-45849142177 10.1152/ajpgi.00051.2008
75. Kelleher D. L., Hicks K. J., Cox D. S., Williamson R. R., Alpers D. H., Dukes G. E., Randomized, double-blind, placebo (PLA) controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterology and Motility 2008 20 131 132
76. Petrenko A. B., Yamakura T., Baba H., Shimoji K., The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesthesia and Analgesia 2003 97 4 1108 1116 2-s2.0-0141458065 (Pubitemid 37158698)
77. Siu A., Drachtman R., Dextromethorphan: a review of N-methyl-D-aspartate receptor antagonist in the management of pain. CNS Drug Reviews 2007 13 1 96 106 2-s2.0-34247892220 10.1111/j.1527-3458.2007.00006.x (Pubitemid 46697843)
78. Zhou Q., Zhang B., Nicholas Verne G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009 146 1-2 41 46 2-s2.0-70349799526 10.1016/j.pain.2009.06.017
79. Zhou Q., Price D. D., Callam C. S., Woodruff M. A., Verne G. N., Effects of the N-Methyl-D-aspartate receptor on temporal summation of second pain (Wind-up) in irritable bowel syndrome. Journal of Pain 2011 12 2 297 303 2-s2.0-79551603862 10.1016/j.jpain.2010.09.002
80. Cremonini F., Camilleri M., McKinzie S., Carlson P., Camilleri C. E., Burton D., Thomforde G., Urrutia R., Zinsmeister A. R., Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. American Journal of Gastroenterology 2005 100 3 652 663 2-s2.0-16844364043 10.1111/j.1572-0241.2005.41081.x (Pubitemid 40487566)
81. Sweetser S., Camilleri M., Linker Nord S. J., Burton D. D., Castenada L., Croop R., Tong G., Dockens R., Zinsmeister A. R., Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? American Journal of Physiology 2009 296 6 G1299 G1306 2-s2.0-67049095870 10.1152/ajpgi.00011.2009
82. Klooker T. K., Kuiken S. D., Lei A., Boeckxstaens G. E., Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2007 26 4 605 615 2-s2.0-34547459065 10.1111/j.1365-2036.2007. 03398.x (Pubitemid 47174283)
83. Whitfield K. L., Schulman R. J., Treatment options for functional gastrointestinal disorders: from empiric to complementary approaches. Pediatric Annals 2009 38 5 288 294 2-s2.0-67149084942 10.9999/00904481-20090420-02
84. Whorwell P. J., Behavioral therapy for IBS. Nature Clinical Practice Gastroenterology & Hepatology 2009 6 148 149 10.1038/ncpgasthep1361
85. Banchard E. B., Lackner J. M., Sanders K., A controller evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behaviour Research and Therapy 2007 45 633 648 10.1016/j.brat.2006.07.003 (Pubitemid 46282624)
86. Bursch B., Psychological/cognitive behavioral treatment of childhood functional abdominal pain and irritable bowel syndrome. Journal of Pediatric Gastroenterology and Nutrition 2008 47 5 706 707 2-s2.0-59849120138 10.1097/01.mpg.0000338967.47679.e9
87. Koob G. F., Heinrichs S. C., A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Research 1999 848 1-2 141 152 2-s2.0-0033457357 10.1016/S0006-8993(99)01991-5 (Pubitemid 30001663)
88. Evangelista S., Benefits from long-term treatment in irritable bowel syndrome. Gastroenterology Research and Practice 2012 2012 6 936960 10.1155/2012/936960
89. Svedlund J., Sjodin I., Ottosson J., Dotevall G., Controlled study of psychotherapy in irritable bowel syndrome. The Lancet 1983 2 8350 589 592 2-s2.0-0020572632 (Pubitemid 13051045)
90. Zijdenbos I. L., de Wit N. J., van der Heijden G. J., Rubin G., Quartero A. O., Psychological treatments for the management of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2009 1 CD006442 2-s2.0-62449316463
91. Lackner J. M., Jaccard J., Krasner S. S., Katz L. A., Gudleski G. D., Blanchard E. B., How does cognitive behavior therapy for irritable bowel syndrome work? A Mediational Analysis of a Randomized Clinical Trial. Gastroenterology 2007 133 2 433 444 2-s2.0-34547512969 10.1053/j.gastro.2007.05. 014 (Pubitemid 47187342)
92. Dorn S. D., Systematic review: self-management support interventions for irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2010 32 4 513 521 2-s2.0-77954745406 10.1111/j.1365-2036.2010.04374.x
93. Mayer E. A., Irritable bowel syndrome. New England Journal of Medicine 2008 358 16 1692 1699 2-s2.0-42249114703 10.1056/NEJMcp0801447 (Pubitemid 351549916)
94. Hungin A. P. S., Self-help interventions in irritable bowel syndrome. Gut 2006 55 5 603 604 2-s2.0-33646229798 10.1136/gut.2005.075606
95. Ljòttson B., Andersson G., Andersson E., Hedman E., Lindfors P., Andrèewitch S., Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterology 2011 11 110 1 13 10.1186/1471-230X-11-1
96. Lackner J. M., Gudleski G. D., Keefer L., Krasner S. S., Powell C., Katz L. A., Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clinical Gastroenterology and Hepatology 2010 8 5 426 432 2-s2.0-77950866429 10.1016/j.cgh.2010.02.007
97. Reme S. E., Kennedy T., Jones R., Darnley S., Chalder T., Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care. Journal of Psychosomatic Research 2010 68 4 385 388 2-s2.0-77949610047 10.1016/j. jpsychores.2010.01.003
98. Micocka-Walus A., Treatment of psychosocial co-morbidities in comm on Gastrointestinal and hepatologic disorders. World Journal of Gastrointestinal Pharmacology and Therapeutics 2010 1 2 64 71 10.4292/wjgpt.v1.i2.64
99. Tan G., Hammond D. C., Gurrala J., Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action. American Journal of Clinical Hypnosis 2005 47 3 161 178 2-s2.0-13444271568 (Pubitemid 40209311)
100. Wilson S., Maddison T., Roberts L., Greenfield S., Singh S., Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2006 24 5 769 780 2-s2.0-33747339412 10.1111/j.1365-2036.2006.03028.x
101. Webb A. N., Kukuruzovic R. H., Catto-Smith A. G., Sawyer S. M., Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2007 4 CD005110 2-s2.0-38449122752
102. Flick C. E., van Rood Y. R., Laan W., Smout A., Weusten B., Whorwell P. J., de Wit N. J., A randomized controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). BMC Gastroenterology 2011 11 137 1 10 10.1186/1471-230X-11-1
103. Lindfors P., Unge P., Arvidsson P., Nyhlin H., Bjornsson E., Abrahammson H., Effects of gut-directed hypnotherapy on IBS in different clinical settingsresults from two randomized, controlled trials. The American Journal of Gastroenterology 2012 107 2 276 285 10.1038/ajg.2011.340
104. Creed F., Guthrie E., Psychological treatments of the irritable bowel syndrome: a review. Gut 1989 30 11 1601 1609 2-s2.0-0024329257 (Pubitemid 20001166)
105. Enck P., Junne F., Klosterhalfen S., Zipfel S., Martens U., Therapy options in irritable bowel syndrome. European Journal of Gastroenterology and Hepatology 2010 22 12 1402 1411 2-s2.0-78349249028 10.1097/MEG.0b013e3283405a17
106. Keefer L., Blanchard E. B., A one year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome. Behaviour Research and Therapy 2002 40 5 541 546 2-s2.0-0036211364 10.1016/S0005-7967(01)00065-1 (Pubitemid 34270465)
107. Tovey P. A., A single-blind trial of reflexology for irritable bowel syndrome. British Journal of General Practice 2002 52 474 19 23 2-s2.0-0036148048 (Pubitemid 34092313)
108. Creed F., Fernandes L., Guthrie E., Palmer S., Ratcliffe J., Read N., Rigby C., Thompson D., Tomenson B., The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003 124 2 303 317 2-s2.0-0037309719 10.1053/gast.2003.50055 (Pubitemid 36169247)
109. Spiller R., Aziz Q., Creed F., Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 1770 1798 (Pubitemid 350206308)